We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ComGenex Announces Extension of the Medicinal Chemistry Synthesis Space
News

ComGenex Announces Extension of the Medicinal Chemistry Synthesis Space

ComGenex Announces Extension of the Medicinal Chemistry Synthesis Space
News

ComGenex Announces Extension of the Medicinal Chemistry Synthesis Space

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ComGenex Announces Extension of the Medicinal Chemistry Synthesis Space"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ComGenex, Inc. has disclosed that it has tested and completed the initial phase of the integration of the first ever continuous flow, bench top ozonolyzis unit into its high-throughput organic synthesis technology line.

The O-Cube is member of the Cube-series developed by Thales Nanotechnology Inc., a former spin-out of ComGenex.

This device is designed to utilise proprietary technologies, including microfluidics and internal ozone generation in order to safely carry out a wide variety of organic transformations under pressure and even at room temperature.

The shoe-box sized unit is fully portable and easy to use in small scale with individual compounds.

According to Dr. Ferenc Darvas, President and Chairman of Thales Nanotechnology, "We believe that the introduction of safe ozonolyzis into routine laboratory practice will significantly enlarge the toolkit of present-day medicinal chemists."

"The application of ozonolyzis, an important chemical transformation, has so far been seriously limited due to the high explosion risk and the low reaction temperature (typically -30 to -40 Celsius). Upon the positive laboratory results achieved at ComGenex, we strive to speed up the commercial launch of O-Cube."

Dr. Laszlo Urge, CEO of ComGenex, Inc. commented, "ComGenex has tested this unit extensively and used it in the production of exclusive compound libraries."

"According to our experience, the device can create compounds that can not be synthesised by conventional batch technologies."

"Therefore, it will open new avenues in the field of medicinal chemistry and it will also contribute to the increase of the chemical diversity in compound libraries. It also provides great support to our ongoing medicinal chemistry projects."

"Once it is commercially available, we expect that, as with its predecessor the H-Cube, it will revolutionise the way ozonolyzis is carried out in medicinal chemistry labs in the future."

Advertisement